The PI3K inhibitor, taselisib, has a unique mechanism of action that leads to enhanced potency in PIK3CA mutant models

被引：3
|
作者：
Song, Kyung W.
Edgar, Kyle A.
Kirkpatrick, Donald S.
Phu, Lilian
Schmidt, Stephen
Nannini, Michelle
Hong, Rebecca
Cheng, Eric
Crocker, Lisa
Young, Amy
Sampath, Deepak
Friedman, Lori
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-146
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
146
引用
收藏
页数：2
相关论文
共 50 条
  • [1] The PI3K inhibitor, taselisib, has enhanced potency in PIK3CA mutant models through a unique mechanism of action
    Friedman, L. S.
    Edgar, K. A.
    Song, K.
    Schmidt, S.
    Kirkpatrick, D. S.
    Phu, L.
    Nannini, M. A.
    Hong, R.
    Cheng, E.
    Crocker, L.
    Young, A.
    Sampath, D.
    CANCER RESEARCH, 2017, 77
  • [2] The PI3K inhibitor, taselisib (GDC-0032), has enhanced potency in PIK3CA mutant models through a unique mechanism of action
    Edgar, Kyle A.
    Song, Kyung
    Schmidt, Stephen
    Kirkpatrick, Don
    Phu, Lilian
    Nannini, Michelle
    Hong, Rebecca
    Cheng, Eric
    Young, Amy
    Sampath, Deepak
    Friedman, Lori S.
    CANCER RESEARCH, 2016, 76
  • [3] Characterization of the enhanced potency of PI3K inhibitor taselisib (GDC-0032) in PI3K mutant cell lines and models
    Edgar, Kyle A.
    Nannini, Michelle
    Hong, Rebecca
    Eigenbrot, Charlie
    Schmidt, Stephen
    Young, Amy
    Sampath, Deepak
    Wallin, Jeffrey J.
    Friedman, Lori S.
    CANCER RESEARCH, 2015, 75
  • [4] Determination of the PI3Kα selective inhibitor alpelisib mechanism of action and efficacy in ER+/ PIK3CA mutant breast cancer preclinical models
    Fritsch, Christine
    Pfister, Estelle
    Ebel, Nicolas
    Guthy, Daniel
    Schnell, Christian
    Hofmann, Francesco
    CANCER RESEARCH, 2018, 78 (13)
  • [5] Dual PI3K/mTOR inhibition in PIK3CA mutant pancreatic cancers
    Payne, Susan
    Depke, Mitchell
    Yueh, Alex
    Sharick, Joseph T.
    Favreau, Peter F.
    Pasch, Cheri A.
    Clipson, Linda
    Matkowskyj, Kristina A.
    Skala, Melissa
    Deming, Dustin A.
    CANCER RESEARCH, 2018, 78 (13)
  • [6] Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers
    Jhaveri, Komal
    Chang, Matthew T.
    Juric, Dejan
    Saura, Cristina
    Gambardella, Valentina
    Melnyk, Anton
    Patel, Manish R.
    Ribrag, Vincent
    Ma, Cynthia X.
    Aljumaily, Raid
    Bedard, Philippe L.
    Sachdev, Jasgit C.
    Dunn, Lara
    Won, Helen
    Bond, John
    Jones, Surai
    Savage, Heidi M.
    Scaltriti, Maurizio
    Wilson, Timothy R.
    Wei, Michael C.
    Hyman, David M.
    CLINICAL CANCER RESEARCH, 2021, 27 (02) : 447 - 459
  • [7] Aspirin has a better effect on PIK3CA mutant colorectal cancer cells by PI3K/Akt/Raptor pathway
    Zhihang Chen
    Chun Wang
    Hao Dong
    Xing Wang
    Feng Gao
    Sen Zhang
    Xiaolong Zhang
    Molecular Medicine, 2020, 26
  • [8] Aspirin has a better effect on PIK3CA mutant colorectal cancer cells by PI3K/Akt/Raptor pathway
    Chen, Zhihang
    Wang, Chun
    Dong, Hao
    Wang, Xing
    Gao, Feng
    Zhang, Sen
    Zhang, Xiaolong
    MOLECULAR MEDICINE, 2020, 26 (01)
  • [9] Phase I evaluation of the PI3 kinase (PI3K) inhibitor taselisib (GDC-0032) in multiple locally advanced or metastatic PIK3CA mutant solid tumor types.
    Jhaveri, Komal L.
    Bedard, Philippe L.
    Cejalvo, Juan Miguel
    Hart, Lowell L.
    Juric, Dejan
    Kelly, Karen
    Lockhart, A. Craig
    Melnyk, Anton
    Moore, Kathleen N.
    Nemunaitis, John J.
    Oliveira, Mafalda
    Patel, Manish R.
    Sachdev, Jasgit
    Smith, David
    VanderWalde, Ari
    Ware, Joseph A.
    Jin, Huan
    Wilson, Timothy R.
    Wei, Michael C.
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] Differential response to a dual PI3K/mTOR inhibitor in PIK3CA mutant urothelial cancer patient derived xenografts
    Elbanna, May F.
    Ciamporcero, Eric
    Adelaiye, Remi
    Orillion, Ashley
    Chintala, Sreenivasulu
    Pili, Roberto
    CANCER RESEARCH, 2016, 76
12345